BCRX FY 2024 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$451M+36.0% YoY

Gross Profit

$438M97.2% margin

Operating Income

-$3M-0.6% margin

Net Income

-$89M-19.7% margin

EPS (Diluted)

$-0.43

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$53M

Stock-Based Comp.

$65M

Balance Sheet

Total Assets

$490M

Total Liabilities

$966M

Stockholders' Equity

-$476M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$451M	$331M	+36.0%
Gross Profit	$438M	$327M	+34.1%
Operating Income	-$3M	-$104M	+97.5%
Net Income	-$89M	-$227M	+60.8%